| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CH |
| Uniprot No | Q96LL4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-319aa |
| 氨基酸序列 | MAICPELAQTDKSALANLSDETETLKNSTDEVQTSSSFSSSGGRQSSPLTSGSKLEREKQTPSLEQGDTQSELLDYKNYEKKLSKKWINYLKLKDSNFERHQPDTKLPTEITRVSDEELNALQSYCTMKINLIHRRGDSKKKTSSRHKKLHLGLDVEASERDAFSCTVPDELLNRIYFKNMRTTPKQEAAAKQHISYQCPYCNRKRAELALSAFLKQKKTLLESFLLQERIDEHLHTKDFLTRIGEAHQDFPRLSDDPRIIWKRLTEKSHIRYSGFERSETEQKLQRDGNSACHLPFSLPFLKRLTLIKPELVIVNDNV |
| 预测分子量 | 36,7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组蛋白(假设"CH"为某类结构域或特定蛋白)的示例参考文献，供参考使用(注：以下为模拟示例，实际文献需通过学术数据库检索)：
---
1. **"Expression and Purification of Recombinant CH Domain Proteins for Structural Studies"**
*作者：Smith A, et al.*
摘要：本研究报道了一种高效表达和纯化含有钙调蛋白同源(CH)结构域的重组蛋白的方法，通过大肠杆菌系统优化，获得了高纯度蛋白用于X射线晶体学分析。
---
2. **"Functional Characterization of a Recombinant CHIP E3 Ubiquitin Ligase in Protein Quality Control"**
*作者：Zhang L, et al.*
摘要：文章阐明了重组表达的CHIP蛋白(C-terminus of Hsc70-interacting protein)通过泛素化途径调控热休克蛋白客户蛋白降解的分子机制，为疾病治疗提供靶点。
---
3. **"Recombinant CH2 Domain of IgG as a Modular Scaffold for Drug Delivery"**
*作者：Johnson R, et al.*
摘要：研究利用重组表达的人源IgG抗体重链恒定区(CH2)构建药物递送载体，证实其低免疫原性和稳定性，为生物制剂开发提供新策略。
---
4. **"Antiviral Activity of Recombinant Coronavirus CH Spike Protein in Vaccine Development"**
*作者：Wang Y, et al.*
摘要：通过杆状病毒系统表达冠状病毒刺突蛋白的CH结构域重组蛋白，验证其诱导中和抗体的能力，为疫苗设计提供实验依据。
---
**提示**："CH"可能对应不同蛋白缩写，建议结合具体研究方向(如结构域类型、疾病关联等)在PubMed、Google Scholar等平台检索，关键词示例：
`"recombinant CH protein"`、`"CH domain expression"`、`"CHIP protein purification"`。
**Background of CH Recombinant Proteins**
Recombinant CH proteins, often referring to proteins engineered with conserved domains (e.g., CH1. CH2. CH3 regions in antibodies), are critical tools in biotechnology and therapeutic development. These proteins are synthesized using recombinant DNA technology, where target genes encoding specific domains are inserted into host systems (e.g., *E. coli*, yeast, or mammalian cells) for expression. The "CH" nomenclature typically relates to constant heavy-chain regions in immunoglobulins, which play structural and functional roles in antibody stability, effector functions, and interactions with immune cells.
The development of CH recombinant proteins accelerated with advancements in genetic engineering and structural biology. For instance, modifying CH domains (e.g., Fc regions) allows optimization of antibody half-life, binding to Fc receptors, or reduced immunogenicity, enhancing therapeutic efficacy. Such engineering is pivotal in designing monoclonal antibodies, bispecific antibodies, and Fc-fusion proteins used in cancer immunotherapy, autoimmune diseases, and infectious diseases.
Beyond therapeutics, CH recombinant proteins serve as research tools to study protein-protein interactions, immune responses, and antigen-antibody binding mechanisms. They are also employed in diagnostic assays, vaccine development, and industrial enzymes.
Challenges include ensuring proper post-translational modifications (e.g., glycosylation in CH domains) for functional activity, which often necessitates mammalian expression systems. Innovations in cell culture, CRISPR-based editing, and AI-driven protein design continue to refine CH protein production, scalability, and application diversity. Overall, CH recombinant proteins underpin modern biologics, bridging molecular insights with clinical and industrial solutions.
(Word count: 249)
×
